-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Initiates Coverage On BridgeBio Oncology with Buy Rating, Announces Price Target of $27

Benzinga·09/15/2025 11:58:47
Listen to the news
HC Wainwright & Co. analyst Robert Burns initiates coverage on BridgeBio Oncology (NASDAQ:BBOT) with a Buy rating and announces Price Target of $27.